Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01560377 · ClinicalTrials.gov registry record · Phase 1
Perfusion Assessment in Laparoscopic Left Anterior Resection
A Phase 1 study, sponsored by Novadaq Technologies ULC, now a part of Stryker.
- Completed
- Registry status
- Phase 1
- Development phase
- 147
- Enrollment target
NCT01560377: Completed Phase 1 study, sponsored by Novadaq Technologies ULC, now a part of Stryker.
NCT01560377 is a Phase 1 study that has completed, run by Novadaq Technologies ULC, now a part of Stryker. The registered enrollment target is 147 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01560377, a Phase 1 study, has completed, sponsored by Novadaq Technologies ULC, now a part of Stryker.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 147 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic left colectomy. This information will provide the surgeon with clinically relevant information in assessing whether or not the tissue has adequate blood supply in the lower section of the colon prior to a colectomy.
Primary Outcome
To demonstrate the utility of intra-operative assessment of colon perfusion, using the PINPOINT System to optimize the location at which to transect the colon in laparoscopic left colectomies and to assess mucosal perfusion of the completed anastomosis following proximal anastomosis in laparoscopic left colectomy.
Interventions
- DEVICE PINPOINT Endoscopic Fluorescence Imaging System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-11 |
| Phase | Phase 1 |
What the finished NCT01560377 record still lists
NCT01560377 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (145% higher).
The record links to 0 conditions, and to 1 intervention - of which PINPOINT Endoscopic Fluorescence Imaging System is the first listed.
NCT01560377 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01560377 about?
NCT01560377 is a clinical study titled "Perfusion Assessment in Laparoscopic Left Anterior Resection". The purpose of this study is to demonstrate that NIR fluorescence angiography using the PINPOINT Endoscopic Fluorescence Imaging System ("PINPOINT System" or "PINPOINT") can assess viability of colon tissue during laparoscopic left colectomy. This information will provide the surgeon with clinically...
What is the current status of trial NCT01560377?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 147 participants. The study started on 2012-05. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01560377?
The interventions under investigation include: PINPOINT Endoscopic Fluorescence Imaging System (DEVICE).
Who is sponsoring clinical trial NCT01560377?
This trial is sponsored by Novadaq Technologies ULC, now a part of Stryker, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01560377's enrollment target sits among peer trials
147 387th of 2000 higher than 1,610 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04396613 · 147 participants · NA
Wound Closure Techniques in Primary Spine Surgery
- NCT04851119 · 147 participants · Phase 1
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- NCT05523947 · 147 participants · Phase 1
Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
- NCT06121843 · 147 participants · Phase 1
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia